A5089434174- Mosquito-borne diseases and control
- Vaccine Coverage and Hesitancy
- Bacterial Infections and Vaccines
- Viral Infections and Outbreaks Research
- Virology and Viral Diseases
- Pneumonia and Respiratory Infections
- Viral Infections and Vectors
- Vibrio bacteria research studies
- Biotechnology and Related Fields
- Innovation and Socioeconomic Development
- Hepatitis Viruses Studies and Epidemiology
- vaccines and immunoinformatics approaches
- Hepatitis B Virus Studies
- Cardiac Valve Diseases and Treatments
- Cardiovascular Function and Risk Factors
- Immunodeficiency and Autoimmune Disorders
- Science and Education Research
- Zoonotic diseases and public health
- SARS-CoV-2 and COVID-19 Research
- Rabies epidemiology and control
- Diphtheria, Corynebacterium, and Tetanus
- Misinformation and Its Impacts
- CRISPR and Genetic Engineering
- Malaria Research and Control
- Immune responses and vaccinations
Fundação Oswaldo Cruz
2012-2021
Rockefeller University
2019
Ministério da Saúde
2010-2019
Universidade Federal Fluminense
2015
Instituto de Tecnologia e Pesquisa
2009
Escola Nacional de Saúde Pública
2008
Ministério da Saúde
2003-2004
Sociedade Brasileira de Pediatria
2003
Universidade de Brasília
2003
Vaccination against measles, mumps, and rubella (MMR) yellow fever (YF) with live attenuated viruses can rarely cause life-threatening disease. Severe illness by MMR vaccines be caused inborn errors of type I and/or III interferon (IFN) immunity (mutations in IFNAR2, STAT1, or STAT2). Adverse reactions to the YF vaccine have remained unexplained. We report two otherwise healthy patients, a 9-yr-old boy Iran severe measles disease at 1 yr 14-yr-old girl Brazil viscerotropic 12 yr. The Iranian...
To verify if the Bio-Manguinhos 17DD yellow fever vaccine (17DD-YFV) used in lower doses is as immunogenic and safe current formulation.
A randomized trial was conducted to assess the immunogenicity and reactogenicity of yellow fever vaccines (YFV) given either simultaneously in separate injections, or 30 days more after a combined measles-mumps-rubella (MMR) vaccine. Volunteers were also YFV produced from 17DD WHO-17D-213 substrains. The study group comprised 1769 healthy 12-month-old children brought health care centers Brasilia for routine vaccination. type frequency expected no severe adverse event associated...
The live attenuated 17DD Yellow Fever vaccine is one of the most successful prophylactic interventions for controlling disease expansion ever designed and utilized in larger scale. However, increase on worldwide demands manufacturing restrictions urge more detailed dose sparing studies. establishment complementary biomarkers addition to PRNT Viremia could support a secure decision-making regarding use YF subdoses. present work aimed at comparing serum chemokine cytokine kinetics triggered by...
Background. The live attenuated yellow fever (YF) vaccines have been available for decades and are considered highly effective one of the safest worldwide. Methods. impact YF-17DD-antigens recall on cytokine profiles YF-17DD-vaccinated children were characterized using short-term cultures whole blood samples single-cell flow cytometry. This study enrolled seroconverters nonseroconverters after primovaccination (PV-PRNT+ PV-PRNT−), revaccination (RV-PRNT+), unvaccinated volunteers (UV-PRNT−)....
Yellow fever vaccine was considered one of the safest vaccines, but in recent years it found that could rarely cause invasive and disseminated disease some otherwise healthy individuals, with high lethality. After extensive studies, although risk factors have been identified, real causes this serious adverse event are largely unknown, findings point to individual host factors. Meningoencephalitis, once happen only children less than 6 months age, has also identified older adults, good...
A single vaccination of Yellow Fever vaccines is believed to confer life-long protection. In this study, results vaccinees who received a dose 17DD-YF immunization followed over 10 y challenge premise. YF-neutralizing antibodies, subsets memory T and B cells as well cytokine-producing lymphocytes were evaluated in groups adults before (NVday0) after (PVday30-45, PVyear1-4, PVyear5-9, PVyear10-11, PVyear12-13) primary vaccination. antibodies decrease significantly from PVyear1-4 PVyear12-13...
In 2009, Bio-Manguinhos conducted a dose-response study with the yellow fever vaccine, administering vaccine in usual mean dose of 27,476 IU (full dose, reference) and tapered doses (10,447 IU, 3013 587 158 31 IU) by subcutaneous route volume (0.5 mL). Tapered were obtained dilution manufacturer's laboratory, test batches presented industrial quality. Doses down to showed similar immunogenicity full (27,476, reference), while displayed lower immunogenicity. Seropositivity was maintained at...
Maternal vaccination is an important area of research and requires appropriate internationally comparable definitions safety standards. The GAIA group, part the Brighton Collaboration was created with mandate proposing standardised applicable to maternal vaccine research. This study proposes international for neonatal infections. infections working group performed a literature review using Medline, EMBASE Cochrane collaboration collected in use public health networks. common criteria derived...
ABSTRACT Yellow fever (YF) vaccines (17D-204 and 17DD) are well tolerated cause very low rates of severe adverse events (YEL-SAE), such as serious allergic reactions, neurotropic diseases (YEL-AND), viscerotropic (YEL-AVD). Viral host factors have been postulated to explain the basis YEL-SAE. However, mechanisms underlying occurrence YEL-SAE remain unknown. The present report provides a detailed immunological analysis 23-year-old female patient. patient developed suspected case YEL-AVD with...
The smallpox worldwide eradication was the major world public health achievement. binomial - vaccines and immunization continues to demonstrate very high performance in prevention control of other diseases preventable by vaccination. new global initiatives on vaccination, such as GAVI, have made possible introduction important preventing million children deaths poorest countries world. National Immunization Program Brazil is also being strengthened, with several into basic calendar...
Viscerotropic disease (VD), a with high mortality, results from the dissemination of yellow fever vaccine virus throughout body. Twenty-six cases VD following vaccination Bio-Manguinhos 17DD were reported, 21 Brazil and 5 other countries, which 19 confirmed, 4 probable 3 suspect. These not related to immunodeficiency diseases, but could be existence autoimmune such as systemic lupus erythematosus. Adverse neurological events are in general aseptic meningitis, good outcome, encephalitis,...
Background This study aimed to compare the cytokine-mediated immune response in children submitted primary vaccination with YF-17D-213/77 or YF-17DD yellow fever (YF) substrains. Methods A non-probabilistic sample of eighty healthy vaccinated (PV) was selected on basis their previously known humoral YF vaccines. The were categorized according YF-neutralizing antibody titers (PRNT) and referred as seroconverters (PV-PRNT+) nonseroconverters (PV-PRNT−). Following revaccination YF-17DD,...
The Yellow Fever (YF) vaccination is recommended for people living in endemic areas and represents the most effective strategy to reduce risk of infection. Previous studies have warned that booster regimens should be considered guarantee long-term persistence 17DD-YF-specific memory components adults with YF-virus circulation. Considering lower seroconversion rates observed children (9-12 month age) as compared adults, this study was designed order access duration immunity single-dose...
Vaccination is the most important measure for prevention and control of yellow fever. It recommended by World Health Organization (WHO) residents endemic areas travelers to risk areas. In 2013, WHO discontinued recommendation booster doses every 10 years, indicating a single dose as sufficient lifelong protection.Considering lower immune response YF vaccine in children compared adults, this study was set out assess duration immunity vaccinated first two years life.This cross-sectional...
The immunogenicity and safety of a new recombinant hepatitis B vaccine from the Instituto Butantan (Butang®) were evaluated in multicenter, double-blind, prospective equivalence study three centers Brazil. Engerix B® was standard vaccine. A total 3937 subjects recruited 2754 (70%) met all protocol criteria at end study. All considered healthy denied having received before Study who adhered to newborn infants (566), children 1 10 years old (484), adolescents 11 19 (740), adults 20 30 (568),...
A randomized, double-blinded study evaluating the immunogenicity, safety and consistency of production a combined diphtheria-tetanus-pertussis-Haemophilus influenzae type b vaccine entirely produced in Brazil by Bio-Manguinhos Instituto Butantan (DTP/Hib-BM) was undertaken. The reference had same DTP but Hib component using purified materials supplied GlaxoSmithKline (DTP/Hib-GSK), which is registered has Brazilian National Immunization Program for over more than five years. One thousand...